Inmune Stock Analysis

INMB
 Stock
  

USD 9.30  0.86  8.46%   

The current price rise of Inmune Bio may raise some interest from investors. The stock closed today at a share price of 9.30 on 57,811 in trading volume. The company management teams may have good odds in positioning the firm resources to exploit market volatility in September. The stock standard deviation of daily returns for 90 days investing horizon is currently 5.63. The very high volatility is mostly attributed to the latest market swings and not very good earnings reports from some of the Inmune Bio partners.
Please see Risk vs Return Analysis.
  
The Inmune Bio stock analysis report makes it easy to digest most publicly released information about Inmune Bio and get updates on important government artifacts, including earning estimates, SEC corporate filings, and announcements. Inmune Stock analysis module also helps to analyze the Inmune Bio price relationship with some important fundamental indicators such as market cap and management efficiency.

Inmune Stock Analysis Notes

About 35.0% of the company shares are held by company insiders. The company has price-to-book (P/B) ratio of 1.88. Some equities with similar Price to Book (P/B) outperform the market in the long run. Inmune Bio recorded a loss per share of 1.59. The entity had not issued any dividends in recent years. INmune Bio, Inc., a clinical-stage immunotherapy company, focuses on developing drugs to reprogram the patients innate immune system to treat disease. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida. Inmune Bio operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 10 people. To learn more about Inmune Bio call the company at 858 964-3720 or check out www.inmunebio.com.

Inmune Bio Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Inmune Bio's investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Inmune Bio or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Inmune Bio is way too risky over 90 days horizon
Inmune Bio appears to be risky and price may revert if volatility continues
The company reported the previous year's revenue of 340 K. Net Loss for the year was (32.69 M) with profit before overhead, payroll, taxes, and interest of 181 K.
Inmune Bio currently holds about 66.73 M in cash with (32.28 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.72.
Inmune Bio has a frail financial position based on the latest SEC disclosures
Roughly 35.0% of the company shares are held by company insiders
Latest headline from www.nasdaq.com: Is Sonos, Inc.s Latest Stock Performance A Reflection Of Its Financial Health - Nasdaq

Inmune Bio Upcoming and Recent Events

Earnings reports are used by Inmune Bio to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Inmune Bio previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
Upcoming Quarterly Report3rd of March 2022
Next Financial Report4th of May 2022
Next Fiscal Quarter End31st of December 2021
Next Fiscal Year End3rd of March 2022
Last Quarter Report30th of September 2021
Last Financial Announcement31st of December 2020

Inmune Largest EPS Surprises

Earnings surprises can significantly impact Inmune Bio's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2019-03-29
2018-12-31-0.19-0.21-0.0210 
2020-03-11
2019-12-31-0.25-0.220.0312 
2021-05-05
2021-03-31-0.27-0.32-0.0518 
View All Earnings Estimates

Inmune Bio SEC Filings

SEC filings are important regulatory documents required of all public companies to provide to potential investors. Inmune Bio prospectus issued under the guidelines of SEC is a legal declaration of facts and statements to ensure that Inmune Bio investors are not misled. SEC filings are required by law to meet strict transparency standards and other important legal constraints. Although many companies may choose careful wording to disguise some material information, SEC filings make crucial Inmune Bio specific information freely available to individual and institutional investors to make a timely investment decision.
3rd of August 2022
Financial Statements and Exhibits. Results of Operations and Financial Condition
View
27th of July 2022
Financial Statements and Exhibits. Other Events
View
25th of July 2022
Financial Statements and Exhibits. Other Events
View
23rd of June 2022
Financial Statements and Exhibits. Other Events
View
16th of June 2022
Financial Statements and Exhibits. Other Events
View
1st of June 2022
Submission of Matters to a Vote of Security Holders
View
24th of May 2022
Financial Statements and Exhibits. Other Events
View
23rd of May 2022
Financial Statements and Exhibits. Other Events
View

Inmune Stock Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Inmune Bio is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Inmune Bio backward and forwards among themselves. Inmune Bio's institutional investor refers to the entity that pools money to purchase Inmune Bio's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Security TypeSharesValue
Janney Montgomery Scott LlcCommon Shares211.3 K1.7 M
Sepio Capital LpCommon Shares22 K194 K
Yorkbridge Wealth Partners LlcCommon Shares10.4 K92 K
Simplex Trading LlcCommon Shares6.3 K55 K
Northwestern Mutual Wealth Management CoCommon Shares4.3 K38 K
Simplex Trading LlcCall Options4.1 K36 K
Simplex Trading LlcPut Options1.7 K15 K
Valley National Advisers IncCommon Shares100010 K
Covington Capital ManagementCommon Shares1000K
Note, although Inmune Bio's institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Inmune Market Capitalization

The company currently falls under 'Small-Cap' category with current market capitalization of 165.94 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Inmune Bio's market, we take the total number of its shares issued and multiply it by Inmune Bio's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities.

Inmune Profitablity

Inmune Bio's profitability indicators refer to fundamental financial ratios that showcase Inmune Bio's ability to generate income relative to its revenue or operating costs. If, let's say, Inmune Bio is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Inmune Bio's executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Inmune Bio's profitability requires more research than a typical breakdown of Inmune Bio's financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
Last ReportedProjected for 2022
Return on Investment(43.70) (47.15) 
Return on Average Assets(0.36) (0.39) 
Return on Average Equity(0.44) (0.47) 
Return on Invested Capital(2.25) (2.42) 
Return on Sales(167.62) (180.86) 

Management Efficiency

The entity has return on total asset (ROA) of (24.25) % which means that it has lost $24.25 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (46.96) %, meaning that it created substantial loss on money invested by shareholders. Inmune Bio management efficiency ratios could be used to measure how well inmune bio manages its routine affairs as well as how well it operates its assets and liabilities. As of August 9, 2022, Return on Investment is expected to decline to -47.15. In addition to that, Return on Average Assets is expected to decline to -0.39. Inmune Bio Total Assets are projected to increase significantly based on the last few years of reporting. The past year's Total Assets were at 99.94 Million. The current year Current Assets is expected to grow to about 89.1 M, whereas Goodwill and Intangible Assets are forecasted to decline to about 14.8 M.
Last ReportedProjected for 2022
Book Value per Share 4.97  4.08 
Enterprise Value over EBIT(4.00) (4.32) 
Enterprise Value over EBITDA(3.69) (3.99) 
Price to Book Value 2.27  2.72 
Tangible Assets Book Value per Share 5.17  5.58 
Enterprise Value112.1 M131.3 M
Tangible Asset Value83.4 M90 M

Technical Drivers

As of the 9th of August, Inmune Bio retains the Risk Adjusted Performance of 0.13, market risk adjusted performance of 0.4001, and Downside Deviation of 6.4. Inmune Bio technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices. Simply put, you can use this information to find out if the firm will indeed mirror its model of historical price patterns, or the prices will eventually revert. We have collected data for nineteen technical drivers for Inmune Bio, which can be compared to its competitors. Please check out Inmune Bio maximum drawdown, and the relationship between the information ratio and downside variance to decide if Inmune Bio is priced fairly, providing market reflects its last-minute price of 9.3 per share. Given that Inmune Bio has jensen alpha of 0.5509, we strongly advise you to confirm Inmune Bio's regular market performance to make sure the company can sustain itself at a future point.

Inmune Bio Price Movement Analysis

The output start index for this execution was twenty-nine with a total number of output elements of thirty-two.
.

Inmune Bio Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Inmune Bio insiders, such as employees or executives, is commonly permitted as long as it does not rely on Inmune Bio's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Inmune Bio insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Inmune Bio Technical and Predictive Indicators

Inmune Bio Forecast Models

Inmune Bio time-series forecasting models is one of many Inmune Bio's stock analysis techniquest aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Inmune Bio's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.

About Inmune Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Inmune Bio stock is reacting to, or reflecting on a current stock market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Inmune shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas, a specific sector, or an individual stock such as Inmune Bio. By using and applying Inmune Stock analysis, traders can create a robust methodology for identifying Inmune entry and exit points for their positions.
Last ReportedProjected for 2022
Gross Margin 0.90  0.89 
INmune Bio, Inc., a clinical-stage immunotherapy company, focuses on developing drugs to reprogram the patients innate immune system to treat disease. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida. Inmune Bio operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 10 people.

Current Inmune Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Inmune analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Inmune analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
37.0Strong Buy2Odds
Inmune Bio current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Inmune analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Inmune stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Inmune Bio, talking to its executives and customers, or listening to Inmune conference calls.
Inmune Analyst Advice Details

Inmune Stock Analysis Indicators

Inmune Bio stock analysis indicators help investors evaluate how Inmune Bio stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Inmune Bio shares will generate the highest return on investment. By understating and applying Inmune Bio stock analysis, traders can identify Inmune Bio position entry and exit signals to maximize returns.
Quick Ratio22.44
Fifty Two Week Low4.63
Revenue Growth3,975.00%
Shares Short Prior Month1.1M
Average Daily Volume Last 10 Day59.72k
Average Daily Volume In Three Month110.75k
Shares Percent Shares Out5.62%
Gross Margins100.00%
Short Percent Of Float8.64%
Forward Price Earnings-5.47
Float Shares11.66M
Fifty Two Week High30.37
Fifty Day Average8.59
Two Hundred Day Average9.79
Enterprise Value To Revenue322.14
Please see Risk vs Return Analysis. Note that the Inmune Bio information on this page should be used as a complementary analysis to other Inmune Bio's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Shere Portfolio module to track or share privately all of your investments from the convenience of any device.

Complementary Tools for Inmune Stock analysis

When running Inmune Bio price analysis, check to measure Inmune Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Inmune Bio is operating at the current time. Most of Inmune Bio's value examination focuses on studying past and present price action to predict the probability of Inmune Bio's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Inmune Bio's price. Additionally, you may evaluate how the addition of Inmune Bio to your portfolios can decrease your overall portfolio volatility.
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Go
Bond Directory
Find actively traded corporate debentures issued by US companies
Go
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Go
CEO Directory
Screen CEOs from public companies around the world
Go
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Go
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Go
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Go
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Go
ETF Directory
Find actively traded Exchange Traded Funds (ETF) from around the world
Go
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Go
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Go
Is Inmune Bio's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Inmune Bio. If investors know Inmune will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Inmune Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
182.3 M
Quarterly Revenue Growth YOY
39.75
Return On Assets
-0.26
Return On Equity
-0.58
The market value of Inmune Bio is measured differently than its book value, which is the value of Inmune that is recorded on the company's balance sheet. Investors also form their own opinion of Inmune Bio's value that differs from its market value or its book value, called intrinsic value, which is Inmune Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Inmune Bio's market value can be influenced by many factors that don't directly affect Inmune Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Inmune Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine Inmune Bio value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Inmune Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.